Mok TS, Kim D, Wu Y, et al. Overall Survival (OS) for First-Line Crizotinib Versus Chemotherapy in ALK+ Lung Cancer: Updated Results from PROFILE 1014. ESMO 2017, abstract LBA50.
Nieuwe medicatie biedt zicht op langere overleving bij HER2+ mammacarcinoom
nov 2020 | Borstkanker